Product Candidates

Femathina™ (MPI-674) is Meditrina’s lead product candidate.  MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year, chronic safety profile that Meditrina is repurposing for endometrial thinning prior to endometrial ablation to treat abnormal uterine bleeding (AUB).  Phase II trials are currently underway.

In addition to MPI-674, Meditrina is evaluating an oral drug for the treatment of ectopic pregnancy (MPI-675), which occurs in one out of 60 pregnancies.  There is currently no approved drug treatment in the US for ectopic pregnancy.  Meditrina is slated to file an IND in this indication in the second half of 2007.

Currently approved for the chronic treatment of estrogen-dependent tumors in postmenopausal women, AIs are being investigated for efficacy in a variety of additional women’s health conditions.  Currently marketed AIs are third generation products, the culmination of more than two decades of drug development efforts.  Meditrina holds the exclusive worldwide rights to several patent applications covering the use of AIs in gynecologic indications.